CABA
Price
$1.92
Change
-$0.06 (-3.03%)
Updated
Sep 30 closing price
Capitalization
339.09M
36 days until earnings call
Intraday BUY SELL Signals
HYFT
Price
$1.32
Change
-$0.05 (-3.62%)
Updated
Sep 30 closing price
Capitalization
63.13M
Intraday BUY SELL Signals
Interact to see
Advertisement

CABA vs HYFT

CABA vs HYFT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CABA vs. HYFT commentary
Oct 01, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CABA is a Buy and HYFT is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
CABA vs HYFT: Fundamental Ratings
CABA
HYFT
OUTLOOK RATING
1..100
5329
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
56
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
8859
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
650

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CABA's Valuation (18) in the null industry is somewhat better than the same rating for HYFT (56). This means that CABA’s stock grew somewhat faster than HYFT’s over the last 12 months.

CABA's Profit vs Risk Rating (100) in the null industry is in the same range as HYFT (100). This means that CABA’s stock grew similarly to HYFT’s over the last 12 months.

CABA's SMR Rating (98) in the null industry is in the same range as HYFT (99). This means that CABA’s stock grew similarly to HYFT’s over the last 12 months.

HYFT's Price Growth Rating (59) in the null industry is in the same range as CABA (88). This means that HYFT’s stock grew similarly to CABA’s over the last 12 months.

HYFT's P/E Growth Rating (100) in the null industry is in the same range as CABA (100). This means that HYFT’s stock grew similarly to CABA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CABAHYFT
RSI
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 29 days ago
88%
Bullish Trend 9 days ago
81%
Declines
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 7 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 01, 2026
Stock price -- (CABA: $1.92 vs. HYFT: $1.33)
Brand notoriety: CABA and HYFT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CABA: 189% vs. HYFT: 63%
Market capitalization -- CABA: $339.09M vs. HYFT: $63.13M
CABA [@Biotechnology] is valued at $339.09M. HYFT’s [@Biotechnology] market capitalization is $63.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CABA’s FA Score shows that 1 FA rating(s) are green while HYFT’s FA Score has 0 green FA rating(s).

  • CABA’s FA Score: 1 green, 4 red.
  • HYFT’s FA Score: 0 green, 5 red.
According to our system of comparison, CABA is a better buy in the long-term than HYFT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CABA’s TA Score shows that 5 TA indicator(s) are bullish while HYFT’s TA Score has 6 bullish TA indicator(s).

  • CABA’s TA Score: 5 bullish, 6 bearish.
  • HYFT’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, HYFT is a better buy in the short-term than CABA.

Price Growth

CABA (@Biotechnology) experienced а -13.51% price change this week, while HYFT (@Biotechnology) price change was -4.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.67%. For the same industry, the average monthly price growth was -10.91%, and the average quarterly price growth was +1.00%.

Reported Earning Dates

CABA is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-2.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CABA
Daily Signal:
Gain/Loss:
HYFT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
KBAB6.35N/A
N/A
KraneShares 2x Long BABA Daily ETF (KBAB)
MAYP33.24-0.01
-0.03%
PGIM S&P 500 Buffer 12 ETF - May (MAYP)
IVVW45.40-0.02
-0.04%
iShares S&P 500 BuyWrite ETF (IVVW)
BIZD12.89-0.08
-0.62%
VanEck BDC Income ETF (BIZD)
FLEE37.91-0.36
-0.95%
Franklin FTSE Europe ETF (FLEE)

HYFT and

Correlation & Price change

A.I.dvisor indicates that over the last year, HYFT has been loosely correlated with RXRX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if HYFT jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HYFT
1D Price
Change %
HYFT100%
-3.99%
RXRX - HYFT
45%
Loosely correlated
+2.48%
LPCN - HYFT
43%
Loosely correlated
+1.85%
PRME - HYFT
39%
Loosely correlated
-1.13%
CABA - HYFT
39%
Loosely correlated
-3.03%
ABCL - HYFT
36%
Loosely correlated
-1.55%
More